🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are escalating globally, with data suggesting over 82 million infections each year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which involves an injection and a pill. The study included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Medical professionals treating patients have shared positive views. Having a one-pill regimen of this kind is seen as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.